Quick Answer
Tevogen Bio Holdings Inc. reported Cash and Equivalents of $129.2 thousand for fiscal year 2022.
Tevogen Bio Holdings Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2022 | $129.2K | -62.5% |
| 2021 | $344.6K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2022 | $143.0K | — | -22.9% |
| June 30, 2022 | $185.6K | — | -19.8% |
| March 31, 2022 | $231.5K | — | -32.8% |
| December 31, 2021 | $344.6K | — | — |
- Tevogen Bio Holdings Inc. showed a decrease of -62.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2021–2022 period, Tevogen Bio Holdings Inc.’s cash and equivalents has declined by 62.5% (from $344.6 thousand to $129.2 thousand).
- The most recent figure is from Tevogen Bio Holdings Inc.’s fiscal year 2022 report (Form 10-K), filed with the SEC on April 17, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: